The Pentacel formula has changed.

The formulation of Pentacel® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate [Tetanus Toxoid Conjugate] Vaccine) has been updated. Sanofi changed the source of Inactivated Polio Virus (IPV) antigen from MRC-5-derived IPV (mIPV) to IPV that is derived from Vero cells (vIPV). This formulation of Pentacel retains the same dosing schedule, indication, safety, and immunogenicity data as the Pentacel formulation customers may use currently. Both formulations of Pentacel can be used to complete the series.

Pentacel formulated with Vero cell-derived IPV will include a different National Drug Code (NDC) number than the formulation you may use currently. It’s important to note the correct NDC number when receiving and administering the vaccine. The NDC number is listed on the outer carton, the vials, in the Prescribing Information, and on the shipment details you receive with your shipment.

Please work with your EHR/EMR to insure the that the new NDC is added to your system.

NDC CPT CVX
Pentacel (with (vIPV) 49281-0511-05 90698 120

Visit https://www.pentacel.com/ or contact Sanofi Pasteur at 1-800-VACCINE (1-800-822-2463) if you have additional questions about the prescribing information and formula changes.

If you have questions about ordering doses for your VFC patients, email our ordering specialists, Christine Wilson and Charma Miller.